Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Hematology"
DOI: 10.1007/s00277-022-04795-x
Abstract: Both characteristics and optimal treatment strategy for hairy cell leukemia-variant (HCL-v) remain elusive due to its rarity. We retrospectively analyzed the clinical features of HCL-v and the efficacy of first-line treatment options in a large… read more here.
Keywords: leukemia variant; purine nucleoside; treatment; cell leukemia ... See more keywords
Hairy Cell Leukemia Variant
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-110192
Abstract: Introduction: Hairy cell leukemia-variant (HCL-V) is an uncommon disorder, accounting for approximately 0.4% of chronic lymphoid malignancies and 10% of all HCL cases, without sexual predominance. Here is an attempt to submit a rare case… read more here.
Keywords: cell leukemia; hairy cell; cell; leukemia variant ... See more keywords
Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant.
Sign Up to like & getrecommendations! Published in 2021 at "Blood advances"
DOI: 10.1182/bloodadvances.2021005039
Abstract: Hairy cell leukemia variant (HCLv) responds poorly to purine analog monotherapy. Rituximab concurrent with cladribine (CDAR) improves response rate, but long-term outcomes are unknown. We report final results of a phase II study of CDAR… read more here.
Keywords: rituximab; long term; cell leukemia; mrd negative ... See more keywords